Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 copernicus study

American Journal of Ophthalmology

Volumn 155, Issue 3, 2013, Pages 429-437.e7

  Brown, David M ^a   Heier, Jeffrey S ^b   Clark, W Lloyd ^c   Boyer, David S ^d   Vitti, Robert ^e   Berliner, Alyson J ^e   Zeitz, Oliver ^f,g   Sandbrink, Rupert ^f,h   Zhu, Xiaoping ^e   Haller, Julia A ⁱ  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^c Palmetto Retina Center   (United States)

^d RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; UNCLASSIFIED DRUG; VEGF TRAP EYE;

ABRASION; ACUTE HEART INFARCTION; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA ABRASION; CORNEA INJURY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE DISCOMFORT; EYE INFECTION; EYE INJURY; EYE IRRITATION; EYE PAIN; FEMALE; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM DISEASE; GLAUCOMA; HEART ARRHYTHMIA; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; INFESTATION; INJECTION SITE REACTION; INTRAOCULAR FOREIGN BODY; INTRAOCULAR PRESSURE; IRIS NEOVASCULARIZATION; LACRIMATION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; NEOVASCULARIZATION (PATHOLOGY); NUTRITIONAL DISORDER; OPTIC DISK ANOMALY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCTATE KERATITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA ARTERY OCCLUSION; RETINA EXUDATE; RETINA HEMORRHAGE; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA MACULOPATHY; RETINA PIGMENT EPITHELIOPATHY; RETINA TEAR; RETREATMENT; RHINOPHARYNGITIS; SHAM PROCEDURE; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

EID: 84873738185     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.09.026     Document Type: Article

References (17)

1. J.B. Jonas, I. Kreissig, and R.F. Degenring Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion Graefes Arch Clin Exp Ophthalmol 240 9 2002 782 783
2. X. Ding, J. Li, X. Hu, S. Yu, J. Pan, and S. Tang Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion Retina 31 5 2011 838 845
3. I.U. Scott, P.C. VanVeldhuisen, and N.L. Oden Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10 Ophthalmology 118 2 2011 345 352
4. I.U. Scott, P.C. VanVeldhuisen, and N.L. Oden SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion Ophthalmology 116 3 2009 504 512
5. J.S. Heier, P.A. Campochiaro, and L. Yau Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 4 2012 802 809
6. D. Boyer, J. Heier, and D.M. Brown Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the Phase 3 COPERNICUS Study Ophthalmology 119 5 2012 1024 1032
7. D.M. Brown, P.A. Campochiaro, and R.P. Singh Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 6 2010 1124 1133.e1121
8. A.N. Economides, L.R. Carpenter, and J.S. Rudge Cytokine traps: multi-component, high-Affinity blockers of cytokine action Nat Med 9 1 2003 47 52
9. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 17 2002 11393 11398
10. N. Papadopoulos, J. Martin, and Q. Ruan Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2 2012 171 185
11. M.W. Stewart, and P.J. Rosenfeld Predicted biological activity of intravitreal VEGF Trap Br J Ophthalmol 92 5 2008 667 668
12. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group Arch Ophthalmol 103 12 1985 1796 1806
13. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report Ophthalmology 102 10 1995 1425 1433
14. P.A. Campochiaro, G. Hafiz, and S.M. Shah Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator Mol Ther 16 4 2008 791 799
15. D.V. Do, Q.D. Nguyen, and D. Boyer One-year outcomes of the DA VINCI study of VEGF trap-eye in eyes with diabetic macular edema Ophthalmology 119 8 2012 1658 1665
16. P.A. Campochiaro, D.M. Brown, and C.C. Awh Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 10 2011 2041 2049
17. D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398